GNI Group Ltd.'s (TSE:2160) Shares Bounce 52% But Its Business Still Trails The Industry
GNI Group Ltd. (TSE:2160) shareholders are no doubt pleased to see that the share price has bounced 52% in the last month, although it is still struggling to make up recently lost ground. Looking back a bit further, it's encouraging to see the stock is up 67% in the last year.
In spite of the firm bounce in price, GNI Group may still look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 7.6x, considering almost half of all companies in the Biotechs industry in Japan have P/S ratios greater than 15.4x and even P/S higher than 81x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.
View our latest analysis for GNI Group
How GNI Group Has Been Performing
While the industry has experienced revenue growth lately, GNI Group's revenue has gone into reverse gear, which is not great. It seems that many are expecting the poor revenue performance to persist, which has repressed the P/S ratio. So while you could say the stock is cheap, investors will be looking for improvement before they see it as good value.
Want the full picture on analyst estimates for the company? Then our free report on GNI Group will help you uncover what's on the horizon.How Is GNI Group's Revenue Growth Trending?
In order to justify its P/S ratio, GNI Group would need to produce anemic growth that's substantially trailing the industry.
Retrospectively, the last year delivered a frustrating 17% decrease to the company's top line. However, a few very strong years before that means that it was still able to grow revenue by an impressive 80% in total over the last three years. Although it's been a bumpy ride, it's still fair to say the revenue growth recently has been more than adequate for the company.
Looking ahead now, revenue is anticipated to climb by 42% per annum during the coming three years according to the three analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 60% each year, which is noticeably more attractive.
With this information, we can see why GNI Group is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.
The Key Takeaway
Even after such a strong price move, GNI Group's P/S still trails the rest of the industry. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
We've established that GNI Group maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. It's hard to see the share price rising strongly in the near future under these circumstances.
It is also worth noting that we have found 1 warning sign for GNI Group that you need to take into consideration.
Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:2160
GNI Group
Engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally.
High growth potential and good value.
Market Insights
Weekly Picks

Is this the AI replacing marketing professionals?
Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business
The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery Â
The Infrastructure AI Cannot Be Built Without
Recently Updated Narratives

Realty Income - A Fundamental and Historical Valuation
A Structured Counter‑Analysis of "The Leaking Dreadnought"

Alphabet Inc. (GOOG): The Gemini Era – Consolidating AI Dominance in 2026.
Popular Narratives

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Nu holdings will continue to disrupt the South American banking market

